{"transactions":[{"id":785633,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":48489,"kind":"person","name":"Weber Christophe Pierre","position":1,"cik":"0002011270","reported_name":"Weber Christophe Pierre","relationship":{"director":true}}],"security":"Deferred Stock Units","published_at":"2026-05-11T20:33:16.000Z","date":"2026-05-07","kind":"grant","planned":false,"acquired":true,"shares":2660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $150,500 (representing 70% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $150,500 (representing 70% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $150,500 (representing 70% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant."}],"balance_after":2660,"derivative":{"underlying":"Common Stock","underlying_shares":2660},"source":{"system":"sec-edgar","filing":"0001225208-26-005113","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520826005113/doc4.xml","form_type":"4"}},{"id":785632,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":48489,"kind":"person","name":"Weber Christophe Pierre","position":1,"cik":"0002011270","reported_name":"Weber Christophe Pierre","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-11T20:33:16.000Z","date":"2026-05-07","kind":"grant","planned":false,"acquired":true,"shares":1140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. Reflects a value of $64,500 (representing 30% of the amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant."}],"balance_after":3786,"source":{"system":"sec-edgar","filing":"0001225208-26-005113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520826005113/doc4.xml","form_type":"4"}},{"id":785631,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":48489,"kind":"person","name":"Weber Christophe Pierre","position":1,"cik":"0002011270","reported_name":"Weber Christophe Pierre","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-11T20:33:16.000Z","date":"2026-05-07","kind":"grant","planned":false,"acquired":true,"shares":1767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock in lieu of 80% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of approximately $100,000 (representing 80% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant."}],"balance_after":2646,"source":{"system":"sec-edgar","filing":"0001225208-26-005113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520826005113/doc4.xml","form_type":"4"}},{"id":798968,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":48489,"kind":"person","name":"Weber Christophe Pierre","position":1,"cik":"0002011270","reported_name":"Weber Christophe Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Tax Obligation Award","published_at":"2026-04-28T10:08:54.000Z","date":"2026-04-27","kind":"grant","planned":false,"acquired":true,"shares":78978,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares."}],"balance_after":125345,"derivative":{"exercise_date":"2026-06-01","expiration_date":"2026-06-01","underlying":"Ordinary Shares","underlying_shares":78978},"source":{"system":"sec-edgar","filing":"0001395064-26-000140","document":"wk-form4_1777370932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2011270/000139506426000140/wk-form4_1777370932.xml","form_type":"4"}},{"id":798967,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":48489,"kind":"person","name":"Weber Christophe Pierre","position":1,"cik":"0002011270","reported_name":"Weber Christophe Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"American Depositary Shares","published_at":"2026-04-28T10:08:54.000Z","date":"2026-04-27","kind":"grant","planned":false,"acquired":true,"shares":165370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of American Depositary Shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones.  On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 369,378 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one American Depositary Share.  The RSUs vest on the following schedule: July 1, 2026 (261,114 shares), July 1, 2027 (72,384 shares) and July 1, 2028 (35,850 shares)."}],"balance_after":418803,"source":{"system":"sec-edgar","filing":"0001395064-26-000140","document":"wk-form4_1777370932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2011270/000139506426000140/wk-form4_1777370932.xml","form_type":"4"}},{"id":798966,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":48489,"kind":"person","name":"Weber Christophe Pierre","position":1,"cik":"0002011270","reported_name":"Weber Christophe Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Ordinary Shares","published_at":"2026-04-28T10:08:54.000Z","date":"2026-04-27","kind":"grant","planned":false,"acquired":true,"shares":78900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of ordinary shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones.  On April 27, 2026 the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 174,900 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one Ordinary Share.  The RSUs vest on the following schedule: June 1, 2026 (125,000 shares), June 1, 2027 (32,700 shares) and June 1, 2028 (17,200 shares)."}],"balance_after":1014200,"source":{"system":"sec-edgar","filing":"0001395064-26-000140","document":"wk-form4_1777370932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2011270/000139506426000140/wk-form4_1777370932.xml","form_type":"4"}},{"id":863377,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":48489,"kind":"person","name":"Weber Christophe Pierre","position":1,"cik":"0002011270","reported_name":"Weber Christophe Pierre","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-03-05T00:35:28.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Grant of restricted stock in lieu of 100% yearly cash compensation, following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant."}],"balance_after":879,"source":{"system":"sec-edgar","filing":"0001225208-26-003178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520826003178/doc4.xml","form_type":"4"}},{"id":863376,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":48489,"kind":"person","name":"Weber Christophe Pierre","position":1,"cik":"0002011270","reported_name":"Weber Christophe Pierre","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-03-05T00:35:28.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":556,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted stock to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of restricted stock vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $42,419.50 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant."}],"balance_after":556,"source":{"system":"sec-edgar","filing":"0001225208-26-003178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520826003178/doc4.xml","form_type":"4"}}]}